SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Sugar Ray Robinson — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSugar Ray Robinson
Date of birth1921-05-03
IdentifiersMRN HR-BX003-SYN-TD; SSN (made up) 000-03-9318
Document date1984-10-27
AuthorLangston Pryce-Okonjo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Sixteen-week review after the sick visit. [S]

History of Present Illness

Sugar Ray Robinson returns sixteen weeks after intake with his care partner, four weeks after the sick visit for nausea, loose stools and a slow pulse on donepezil 10 mg. Since returning to 5 mg in the morning his stomach has settled, the vivid dreams stopped, and he has not been dizzy. Metformin and lisinopril were restarted after two days. He had the dilated eye examination two weeks ago, with no retinopathy. He goes to the day program twice a week and to the foundation gym once. His care partner is sleeping better with the day program and the caregiver class. [S]

ElementDetail
Donepezil5 mg each morning; no side effects
Creatinine1.0 mg/dL, from 1.2 at the sick visit
Eye examinationNo diabetic retinopathy
PHQ-93
Care partnerZarit 16, narrative

Review of Systems

SystemResultFinding
GastrointestinalNegativeNo nausea or diarrhea
CardiovascularNegativeNo dizziness or fainting
NeurologicalPositiveMemory loss unchanged; no falls
PsychiatricNegativeMood good; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1,000 mg oral tablet, one tablet twice daily with mealsOne tablet twice daily with mealsOral route1982-03-01activeS
Glipizide 5 mg oral tablet, one tablet before breakfastOne tablet before breakfastOral route1983-01-15 to 1984-08-18completedS
Lisinopril 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1981-06-01activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1982-03-01activeS
Diphenhydramine 25 mg oral capsule, one at bedtime for sleep, bought over the counterOne capsule at bedtimeOral route1983-10-01 to 1984-07-07stoppedS
Donepezil 5 mg oral tablet, one tablet at bedtimeOne tablet at bedtimeOral route1984-08-18 to 1984-09-22completedS
Donepezil 10 mg oral tablet, one tablet at bedtimeOne tablet at bedtimeOral route1984-09-22 to 1984-10-01stoppedS
Donepezil 5 mg oral tablet, one tablet each morning with breakfastOne tablet each morning with breakfastOral route1984-10-01activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1984-10-27Body height180cmS
1984-10-27Body weight75.8kgS
1984-10-27Body mass index (BMI) [Ratio]23.4kg/m2S
1984-10-27Systolic blood pressure126mm[Hg]S
1984-10-27Diastolic blood pressure76mm[Hg]S
1984-10-27Heart rate66/minS
1984-10-27Respiratory rate14/minS
1984-10-27Body temperature36.5CelS
1984-10-27Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1984-10-27Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
1984-10-27Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.74-1.35 mg/dLNormalS
1984-10-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1979)/1.73 sq M85mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1984-10-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 1984-10-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 126/76 seated and 124/74 standing; pulse 66 and regular; weight 75.8 kg
MouthMoist mucous membranes
Mental statusCheerful and engaged; repeats a story once

Problems

ProblemClinical statusVerificationCodeProvenance
Memory loss over about two years, worse in the past six months, with repeated questions, missed appointments and bills, and getting lost twice while driving in familiar streets, reported by him and his care partner; cause to be foundresolvedconfirmed R41.3S — Synthetic presenting problem anchored to his documented Alzheimer's disease; resolved into the diagnosis at the third visit. Not a claim about his real symptoms at that age.
Alzheimer's disease with early onset, confirmed by a positive amyloid PET, with an amnestic presentation; traumatic encephalopathy syndrome, a research diagnosis, consideredactiveconfirmed G30.0S — Synthetic modern diagnosis by current criteria at the third visit; not a retrospective diagnosis of the historical person beyond the documented Alzheimer's disease.
Mild dementia due to Alzheimer's disease (CDR 1, MMSE 22, MoCA 18), without behavioral or psychological symptomsactiveconfirmed F02.A0S — Synthetic stage at diagnosis.
Type 2 diabetes for about ten years on metformin and glipizide; hemoglobin A1c 6.4%, below his goal, with hypoglycemia risk from the sulfonylureaactiveconfirmed E11.9S — Synthetic modern diabetes anchored to his documented diabetes.
Hypertension, controlled on lisinoprilactiveconfirmed I10S — Synthetic modern hypertension anchored to the single press report.
Bilateral sensorineural hearing loss, mild to moderate, high frequencies, on audiometryactiveconfirmed H90.3S — Synthetic finding checked as a modifiable contributor to cognitive difficulty.
Nausea, loose stools, dizziness on standing and a slow pulse (56) nine days after donepezil was raised to 10 mg, with mild dehydration (creatinine 1.2 mg/dL); resolved after returning to 5 mg in the morning and two days of sick-day rulesresolvedconfirmed R11.0S — Synthetic adverse effect of a cholinesterase inhibitor; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyCognitive testing (MoCA, MMSE)At diagnosis, then yearly, or sooner with changeUp to dateNext in six to twelve months
Medication safetyMedicine review for anticholinergic and sedating drugs (Beers)Every visitCompleted todayNo anticholinergic or sedating drugs
SurveyBehavioral and psychological symptoms (NPI-Q items)Every visitCompleted todayNone
Medication safetyCholinesterase inhibitor: benefit, nausea, diarrhea, dreams, pulseEach follow-up and each dose changeCompleted today5 mg each morning tolerated; pulse 66; 10 mg not tolerated (sick visit)
SurveyDepression screen (PHQ-9)At diagnosis and yearlyCompleted today3; item 9 scored 0
Self-managementDriving, firearm and home safetyAt diagnosis and each follow-upCompleted todayNot driving; no firearm in the home; no wandering
Self-managementCare partner support and burden (Zarit, narrative)At diagnosis, then at least yearlyCompleted todayZarit 16, from 18; day program and caregiver class
LaboratoryHemoglobin A1c, goal under 8.0% for an older adult with cognitive impairment, and hypoglycemia reviewEvery three months after a therapy change; every six months when stableUp to date6.9% five weeks ago; no low readings
ExaminationBlood pressure, goal under 130/80 mmHgEvery visitCompleted today126/76 mmHg; no standing drop
LaboratoryPotassium and creatinine on lisinopril and metforminYearly, and after acute illness or dehydrationCompleted todayPotassium 4.4 mmol/L, creatinine 1.0 mg/dL (eGFR 85), back to baseline after the dehydration
ExaminationDilated diabetic eye examinationEvery one to two years without retinopathyCompleted todayDilated examination two weeks ago: no retinopathy
Self-managementExercise and social activityEvery visitCompleted todayDay program exercise, daily walks and the foundation gym

Goal progress:

Guideline basis: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); 13. Older Adults: Standards of Care in Diabetes-2026 (2026); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Practice Parameter update: Evaluation and management of driving risk in dementia (2010); Guiding an Improved Dementia Experience (GUIDE) Model (2024)

Follow-up: Second recombinant zoster dose due two to six months after the first. Review in three months. Call for side effects, falls, low glucose readings or new behavior changes. [S]